Cellebrite appoints Shiven Ramji as new CEO

Cellebrite DI Ltd. reports a leadership transition effective August 13, 2026.

Rhea-AI Filing Summary

Cellebrite DI Ltd. reports a leadership transition effective August 13, 2026. By mutual agreement, Thomas E. Hogan ceased serving as Chief Executive Officer and simultaneously resigned from the company’s board of directors. As part of a planned succession, Shiven Ramji was appointed Chief Executive Officer on the same date, providing continuity at the top management level. Mr. Hogan agreed to serve as an advisor to the company for a period of six months following his departure from his executive and board roles, supporting the transition.

Filing Explained

This Form 6-K furnishes interim material information and is incorporated by reference into the listed Form S-8 registration statements and Form F-3 registration statement, so the report forms part of those registration filings from August 13, 2026, unless later superseded.

Key Terms

planned succession, foreign private issuer, advisor to the Company, incorporated by reference

4 terms

planned succession financial

"Shiven Ramji was appointed Chief Executive Officer as part of a planned succession"

foreign private issuer regulatory

"Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

advisor to the Company financial

"Mr. Hogan resigned ... and agreed to serve as an advisor to the Company"

incorporated by reference regulatory

"The contents of this Report on Form 6-K are incorporated by reference into the Company’s registration statements"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership change did Cellebrite (CLBT) disclose in August 2026?

Cellebrite replaced its CEO effective August 13, 2026, as part of a planned succession, with Thomas E. Hogan stepping down and Shiven Ramji being appointed Chief Executive Officer on the same date.

When did Thomas E. Hogan step down as Cellebrite (CLBT) CEO?

Thomas E. Hogan ceased serving as CEO of Cellebrite effective August 13, 2026, pursuant to a mutual agreement between him and the company, and he also resigned from the board on that date.

Who is the new Chief Executive Officer of Cellebrite (CLBT)?

Cellebrite appointed Shiven Ramji as Chief Executive Officer effective August 13, 2026. His appointment was described as part of a planned succession, coinciding with Thomas E. Hogan’s departure from the CEO role.

Did Thomas E. Hogan remain involved with Cellebrite (CLBT) after resigning?

Yes. After ceasing to serve as CEO and resigning from the board on August 13, 2026, Thomas E. Hogan agreed to act as an advisor to Cellebrite for a six-month period.

Does the Cellebrite (CLBT) CEO change affect its existing SEC registrations?

The company stated that the information is incorporated by reference into its existing Form S-8 and Form F-3 registration statements, so those registrations now reflect this leadership transition.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/13/2026 - 05:12 PM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the month of August 2026

Commission File Number 001-40772

Cellebrite DI Ltd.

(Translation of registrant’s name into English)

94 Shlomo Shmelzer Road

Petah Tikva 4970602, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒        Form 40-F ☐

EXPLANATORY NOTE

As previously disclosed, effective as of August 13, 2026, pursuant to mutual agreement, Thomas E. Hogan ceased serving as Chief Executive Officer of Cellebrite DI Ltd. (the “Company”). Shiven Ramji was appointed Chief Executive Officer as part of a planned succession. In addition, effective as of August 13, 2026, Mr. Hogan resigned from his position on the board of directors of the Company and agreed to serve as an advisor to the Company for a period of six months.

The contents of this Report on Form 6-K are incorporated by reference into the Company’s registration statements on Form S-8 (File Nos. 333-260878, 333-278130 and 333-293973) filed with the SEC on November 8, 2021, March 21, 2024 and March 3, 2026, respectively, and Form F-3 (File No. 333-259826) filed with the SEC on September 13, 2022, to be a part thereof from the date on which this Report on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Cellebrite DI Ltd.
Date: August 13, 2026	By:	/s/ Holly Windham
		Holly Windham
		General Counsel

2